Janis M. Taube

Best Publications

• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  Suzanne L. Topalian;F. Stephen Hodi;Julie R. Brahmer;Scott N. Gettinger

  14371
  Citations

• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

  Dung T. Le;Jennifer N. Uram;Hao Wang;Bjarne R. Bartlett

  10084
  Citations

• Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

  Dung T. Le;Dung T. Le;Jennifer N. Durham;Jennifer N. Durham;Kellie N. Smith;Hao Wang

  6773
  Citations

• Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

  Julie R. Brahmer;Charles G. Drake;Ira Wollner;John D. Powderly

  3544
  Citations

• Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

  Suzanne L. Topalian;Janis M. Taube;Robert A. Anders;Drew M. Pardoll

  2828
  Citations

• Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

  Suzanne L. Topalian;Mario Sznol;David F. McDermott;Harriet M. Kluger

  2649
  Citations

• Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

  Janis M Taube;Alison P. Klein;Julie R Brahmer;Haiying Xu

  2597
  Citations

• Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

  Janis M. Taube;Robert A. Anders;Geoffrey D. Young;Haiying Xu

  2415
  Citations

• Fulminant Myocarditis with Combination Immune Checkpoint Blockade

  Douglas B. Johnson;Justin M. Balko;Margaret L. Compton;Spyridon Chalkias

  2293
  Citations

• The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints

  Nicolas J. Llosa;Michael Cruise;Ada Tam;Elizabeth C. Wicks

  1612
  Citations

• PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

  Paul T. Nghiem;Shailender Bhatia;Evan J. Lipson;Ragini R. Kudchadkar

  1330
  Citations

• Neoadjuvant checkpoint blockade for cancer immunotherapy

  Suzanne L. Topalian;Janis M. Taube;Drew M. Pardoll

  966
  Citations

• Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma

  Sofia Lyford-Pike;Shiwen Peng;Geoffrey D. Young;Janis M. Taube

  845
  Citations

• Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer

  Kristin J. Lastwika;Kristin J. Lastwika;Willie Wilson;Qing Kay Li;Jeffrey Norris

  809
  Citations

• A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non–small cell lung cancer

  David L. Rimm;Gang Han;Janis M. Taube;Eunhee S. Yi

  777
  Citations

• Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody

  Evan J. Lipson;William H. Sharfman;Charles G. Drake;Ira Wollner

  653
  Citations

• Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis

  Steve Lu;Julie E. Stein;David L. Rimm;Daphne W. Wang

  650
  Citations

• PD-1/PD-L1 inhibitors.

  Joel Sunshine;Janis M Taube

  620
  Citations

• Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes.

  Christopher M. Heaphy;Andrea P. Subhawong;Seung Mo Hong;Michael G. Goggins

  596
  Citations

• Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)

  T.R. Cottrell;E.D. Thompson;P.M. Forde;J.E. Stein

  561
  Citations